Predictive Value of Inflammatory Indexes and CHA2DS2-VASc Score for LVT in ANT-MI With Left Ventricular Dysfunction
1 other identifier
observational
371
0 countries
N/A
Brief Summary
To investigate the predictive value of inflammatory indexes and CHA2DS2-VASc score for anterior myocardial infarction (ANT-MI) with left ventricular thrombus(LVT) (LVT).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2014
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2021
CompletedFirst Submitted
Initial submission to the registry
April 25, 2021
CompletedFirst Posted
Study publicly available on registry
May 4, 2021
CompletedMay 4, 2021
April 1, 2021
7 years
April 25, 2021
April 28, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
the predictive of the inflammatory indexes and CHA2DS2-VASc score in LVT
the logistic regression model was established between the indexes and LVT
Day 1
Study Arms (2)
LVT group
left ventricular thrombus in acute anterior myocardial infarction patients with left ventricular dysfunction
non-LVTgroup
acute anterior myocardial infarction patients with left ventricular dysfunction while without LVT
Interventions
inflammatory indexes and CHA2DS2-VASc score
Eligibility Criteria
The study included a total of 371 patients with anterior myocardial infarction (ANT-MI) treated with emergency prior percutaneous coronary intervention (pPCI) in our hospital betweenfrom January 2014 andto January 2021. Patients were eligible for enrollmentenrolment if they had a reduced left ventricularLV ejection fraction (LVEF) ( ≤40%). and if detailed data on demographic and clinical characteristics were documented. Exclusion criteria were end-stage organic disease, thrombotic hematological disorders, previous anticoagulant use, and poor echogenicity (Figure 1). Based on the study criteria, 123 patients were excluded from the study; thus, 248 patients were included in the analysis.
You may qualify if:
- acute anterior myocardial infarction with left ventricular dysfunction
You may not qualify if:
- end-stage organic disease, thrombotic hematological disorders, previous anticoagulant use, and poor echogenicity
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Biospecimen
blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 25, 2021
First Posted
May 4, 2021
Study Start
January 1, 2014
Primary Completion
January 1, 2021
Study Completion
January 1, 2021
Last Updated
May 4, 2021
Record last verified: 2021-04